interleukin-13


Also found in: Dictionary, Thesaurus, Medical.

interleukin-13

[‚in·tər¦lük·ən ′thər‚tēn]
(immunology)
A cytokine produced by activated T lymphocytes that inhibits inflammatory cytokine production induced by bacterial endotoxin and stimulates gamma-interferon production by natural killer cells, enhancing the effect of interleukin-2. Abbreviated IL-13.
References in periodicals archive ?
Impact of interleukin-13 responsiveness on the synthetic and proliferative properties of Th1- and Th2-type pulmonary granuloma fibroblasts.
Evaluation of interleukin-13 in the serum and bronchoalveolar lavage fluid of patients with idiopathic pulmonary fibrosis [in Chinese].
The brief report with 32 pages describes the background of the target, the scientific rationale to develop molecules targeting interleukin-13 or its receptors and current drug discovery approaches.
Currently, Targepeutics' three pharmaceutical platforms are Targepeutics' Genetically Engineered Interleukin-13, Immunotherapy (applications in cancer and asthma), and Anti- tumor Progression (targeting growth and ability of solid tumors to create new blood vessels).
The development of antagonists to the interleukin-13 receptor for the treatment of asthma is one of our priority projects," said Dr.
This patent includes specific variations in the inflammatory gene for interleukin-13 (IL-13) and represents part of our expanding coverage of inflammation genes outside the IL-1 gene cluster," added Kenneth S.
The Company's Interleukin-1 Trap is in a Phase II trial for rheumatoid arthritis, and a dual Trap that blocks both Interleukin-4 and Interleukin-13 is in a Phase I trial for asthma and allergy.
Food and Drug Administration (FDA) to initiate a clinical development program for the Interleukin-4 and Interleukin-13 Dual Cytokine Trap (IL-4/13 Trap) in patients with asthma.
Nasdaq National Market: NEOL) announced today publication of data on its product IL13-PE38, a chimeric protein composed of human interleukin-13 (IL-13) and a truncated form of Pseudomonas exotoxin (PE38QQR).
Over the next year, we also expect to initiate clinical trials of a Vascular Endothelial Growth Factor (VEGF) Trap to block angiogenesis and vascular permeability in settings of cancer and other conditions and a dual Trap for both interleukin-4 and interleukin-13 for asthma/allergies.